Site Maintenance will take place from 4:00 PM on 2024-04-29 to 9:00 AM on 2024-05-01.
Please do not make any content change during this time, otherwise all the changes will be lost.

Select Publications

Book Chapters

Omari SA; Adams MJ; Geraghty DP, 2017, 'TRPV1 Channels in Immune Cells and Hematological Malignancies', in Geraghty DP; Rash LD (ed.), Advances in Pharmacology, pp. 173 - 198, http://dx.doi.org/10.1016/bs.apha.2017.01.002

Journal articles

Moles E; Howard CB; Huda P; Karsa M; McCalmont H; Kimpton K; Duly A; Chen Y; Huang Y; Tursky ML; Ma D; Bustamante S; Pickford R; Connerty P; Omari S; Jolly CJ; Joshi S; Shen S; Pimanda JE; Dolnikov A; Cheung LC; Kotecha RS; Norris MD; Haber M; de Bock CE; Somers K; Lock RB; Thurecht KJ; Kavallaris M; Moles Meler E, 2023, 'Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia', Science translational medicine, 15, pp. eabm1262 - eabm1262, http://dx.doi.org/10.1126/scitranslmed.abm1262

Omari SA; Geraghty DP; Khalafallah AA; Venkat P; Shegog YM; Ragg SJ; de Bock CE; Adams MJ, 2022, 'Optimized flow cytometric detection of transient receptor potential vanilloid-1 (TRPV1) in human hematological malignancies', Medical Oncology, 39, http://dx.doi.org/10.1007/s12032-022-01678-z

Page EC; Heatley SL; Eadie LN; McClure BJ; de Bock CE; Omari S; Yeung DT; Hughes TP; Thomas PQ; White DL, 2022, 'HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort', Oncogene, 41, pp. 797 - 808, http://dx.doi.org/10.1038/s41388-021-02126-4

Van Thillo Q; De Bie J; Seneviratne JA; Demeyer S; Omari S; Balachandran A; Zhai V; Tam WL; Sweron B; Geerdens E; Gielen O; Provost S; Segers H; Boeckx N; Marshall GM; Cheung BB; Isobe K; Kato I; Takita J; Amos TG; Deveson IW; McCalmont H; Lock RB; Oxley EP; Garwood MM; Dickins RA; Uyttebroeck A; Carter DR; Cools J; de Bock CE, 2021, 'Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia', Nature Communications, 12, pp. 4164, http://dx.doi.org/10.1038/s41467-021-24442-9

Boast B; Miosge LA; Kuehn HS; Cho V; Athanasopoulos V; McNamara HA; Sontani Y; Mei Y; Howard D; Sutton HJ; Omari SA; Yu Z; Nasreen M; Daniel Andrews T; Cockburn IA; Goodnow CC; Rosenzweig SD; Enders A, 2021, 'A point mutation in IKAROS ZF1 causes a B cell deficiency in mice', Journal of Immunology, 206, pp. 1505 - 1514, http://dx.doi.org/10.4049/jimmunol.1901464

Boast B; Helian K; Andrews D; Li X; Cho V; Closa A; Sutton H; Reed J; Bergmann H; Roots C; Yabas M; Barthel N; Omari S; Young C; Miosge L; Eyras E; Nutt S; Hein N; Hannan K; Cockburn I; Goodnow C; Enders A, 2021, 'Dysregulation of PAX5 causes uncommitted B cell development and tumorigenesis in mice', , http://dx.doi.org/10.1101/2021.01.29.428877

Omari SA; Adams MJ; Kunde DA; Geraghty DP, 2016, 'Capsaicin-Induced Death of Human Haematological Malignant Cell Lines is Independent of TRPV1 Activation', Pharmacology, 98, pp. 79 - 86, http://dx.doi.org/10.1159/000445437

Omari S; Khalafallah A; Ayesh M; Matalka I; Al-Hadithi R, 2011, 'High serum erythropoietin and ferritin levels in conjunction with anemia response in malignant lymphoma', Mediterranean Journal of Hematology and Infectious Diseases, 3, http://dx.doi.org/10.4084/MJHID.2011.018

Working Papers

Omari SA; Geraghty DP; Khalafallah AA; Venkat P; Shegog YM; Ragg SJ; de Bock CE; Adams MJ, 2021, Optimized Flow Cytometric Detection of Transient Receptor Potential Vanilloid-1 (TRPV1) in Human Hematological Malignancies, medRxiv, http://dx.doi.org10.1101/2021.08.04.21261521


Back to profile page